Technical Analysis for SPRB - Spruce Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.49 | 0.89% | 0.00 |
SPRB closed up 0.89 percent on Wednesday, November 20, 2024, on 40 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
50 DMA Resistance | Bearish | 0.89% | |
NR7 | Range Contraction | 0.89% | |
Lower Bollinger Band Walk | Weakness | 0.89% | |
Lower Bollinger Band Touch | Weakness | 0.89% | |
Oversold Stochastic | Weakness | 0.89% | |
50 DMA Resistance | Bearish | 3.51% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 20 hours ago |
Down 1% | about 20 hours ago |
50 DMA Resistance | about 21 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Rose Above 50 DMA | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.95 |
52 Week Low | 0.4112 |
Average Volume | 433,998 |
200-Day Moving Average | 1.14 |
50-Day Moving Average | 0.49 |
20-Day Moving Average | 0.54 |
10-Day Moving Average | 0.51 |
Average True Range | 0.03 |
RSI (14) | 43.50 |
ADX | 23.63 |
+DI | 13.63 |
-DI | 20.62 |
Chandelier Exit (Long, 3 ATRs) | 0.51 |
Chandelier Exit (Short, 3 ATRs) | 0.57 |
Upper Bollinger Bands | 0.60 |
Lower Bollinger Band | 0.47 |
Percent B (%b) | 0.16 |
BandWidth | 24.69 |
MACD Line | 0.00 |
MACD Signal Line | 0.01 |
MACD Histogram | -0.0099 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.54 | ||||
Resistance 3 (R3) | 0.54 | 0.53 | 0.53 | ||
Resistance 2 (R2) | 0.53 | 0.51 | 0.53 | 0.53 | |
Resistance 1 (R1) | 0.51 | 0.50 | 0.51 | 0.51 | 0.53 |
Pivot Point | 0.49 | 0.49 | 0.49 | 0.49 | 0.49 |
Support 1 (S1) | 0.47 | 0.48 | 0.47 | 0.47 | 0.45 |
Support 2 (S2) | 0.46 | 0.47 | 0.46 | 0.45 | |
Support 3 (S3) | 0.44 | 0.46 | 0.45 | ||
Support 4 (S4) | 0.44 |